carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'tiragolumab']
skyscraper-02 trial presented by randomized, double blind, placebo-controlled study of impower133 regimen +/- tiragolumab (anti-tigit) co-primary endpoints: pfs/os n=490
no difference in pfs/os between tx arms
no substantial difference in aes #asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM